Tonka bean

Tonka Bean (Dipteryx odorata): A Comprehensive Reference

1. Identity: Botanical Classification, Names, and Physical Description

Scientific and Common Names

Dipteryx odorata (commonly known as "cumaru," "kumaru," or "Brazilian teak") is a species of flowering tree in the pea family, Fabaceae. Its seeds are known as tonka beans, but are sometimes spelled tonkin beans or tonquin beans (the spelling variants bear no relation to the historical Tonkin region). In Spanish-speaking parts of Latin America, particularly Venezuela, the seeds are known as sarrapia. The plant is also known regionally as cumaru de cheiro, cumarujo, champagne, muimapagé, tonka fava of Amazonia, amburana, cumaru de big leaf, cumaru yellow, cumarurana, cumaru real, and cumaru de Amazonas. The old genus name, Coumarouna, is of linguistic significance: the old genus name Coumarouna was formed from another Tupi name for the tree, kumaru.

Linguistic Origin of the Name

The word "tonka" is taken from the Galibi (Carib) tongue spoken by natives of French Guiana; it also appears in Tupi, another language of the same region, as the name of the tree. One of the main substances the tonka bean is made of — coumarin — gets its name from another Tupi word for the tree, kumaru.

Botanical Description

Dipteryx odorata is a large tropical tree native to the Amazon basin, found in present-day Venezuela, northern Brazil, Colombia, Suriname, and the Guianas, as well as the nearby islands of Trinidad and Tobago. It grows up to 25–30 meters tall with a trunk diameter of about 1 meter, has smooth grey bark, alternate pinnate leaves that are glossy and dark green, and pink flowers. The tree is native to Northern South America and is semi-deciduous. Remarkably, radio-carbon dating of D. odorata stumps near Manaus showed that it was one of around 100 species that can live to over 1,000 years; until this research, it had been assumed unlikely that any Amazonian tree could live to old age due to rainforest conditions.

The Fruit and Seed (Tonka Bean)

The fruit of Dipteryx odorata resembles a small mango, ripening from dark green into yellow and mahogany. Its fibrous yellow pulp encases a fuzzy, peach-like pit that holds a smooth, black seed. The seeds are black and wrinkled with a smooth, brown interior, and have a strong fragrance similar to sweet woodruff due to their high content of coumarin. When aged in barrels of rum and dried until they take on a shriveled, raisin-like appearance, tonka beans develop a crystallized white coating of coumarin that intensifies their sweet aroma, signaling their many uses in perfumery, cooking, and tobacco manufacturing.

Common Preparations and Commercial Forms

The seed is the commercially traded part of the plant. Cured tonka beans contain approximately 8% water, 2–3% coumarin, and 25% tonka butter. The bean or its extract is used to perfume and flavor food, tobacco, soap, and liqueurs, and also as a substitute for vanilla and as a fixing agent for dyes and perfumes. In concentrated extract form, tonka bean absolute contains approximately 90% coumarin. Among tonka beans' main volatile constituents are alcohols, carbonyl compounds, acids, esters, terpenes, terpenoids, lactones, aliphatic and aromatic hydrocarbons, with coumarin being the dominant compound. The bean is also available in whole dried form, grated directly onto foods like nutmeg, and as infused alcoholic extracts. After harvesting, the beans undergo a drying and fermentation process, which enhances their distinctive aroma.

2. Traditional and Historical Use

Indigenous South American Use

The indigenous peoples of South America have long used tonka beans in rituals and remedies, believing them to have spiritual and therapeutic effects. The name "tonka bean" itself is derived from the Tupi and Galibi languages of Indigenous South America. The Kayapó people (an indigenous group of Brazil) used tonka beans as medicine. D. odorata holds ethnobotanical importance in traditional Amazonian medicine, where it has been employed against respiratory ailments, inflammation, wounds, fever, and digestive disorders, among others.

Among Indigenous groups such as the Warao and Kalinago peoples, the tree is revered as a symbol of divine protection. In the realm of shamanic practices, tonka beans are occasionally incorporated into rapé, a traditional snuff used for meditation and healing.

Traditional Medicinal Preparations

Herbalists prepare poultices by grinding dried beans into a paste mixed with coconut oil or aloe, applying it to alleviate arthritis, muscle pain, or wounds. For respiratory ailments, tonka bean shavings are steeped in hot water with ginger and honey to create a soothing tea for coughs, colds, and nausea. The seeds were often infused in teas or tinctures to relieve symptoms of colds and to ease respiratory discomfort. The beans were also ground into a powder, infused in liquids, or used as part of poultices and salves.

Elders and healers emphasize strict dosing protocols — often using no more than a thumbnail-sized portion of the bean — to avoid coumarin's toxic effects. This cautious approach reflects a nuanced balance between tradition and safety, preserved through oral teachings.

Introduction to Europe and Colonial Trade

Tonka beans were introduced to Europe in the 18th century, where they quickly became popular for their rich vanilla-cinnamon aroma. By the 19th century, they were widely used in perfumery and tobacco flavoring. Historically, tonka beans also played an economic role in Trinidad's colonial-era trade networks. Enslaved and indentured laborers secretly harvested and traded the beans as a form of currency, using their value to barter for goods or freedoms.

Traditional Culinary Use

In traditional kitchens, tonka beans were sparingly grated like nutmeg, their rich, vanilla-like essence elevating desserts. A coumarin-like flavoring can be extracted from the seed through a process of fermentation. It has been used commercially as a vanilla substitute in flavoring a wide range of foods including baked goods, ice cream, and cocoa. In Trinidad, the tonka fruit is eaten whole when ripe.

Coumarin was first isolated from tonka bean in 1820 by Alfred Vogel from Munich, and was first synthesized in 1868 by William Henry Perkin.

3. Key Constituents and Active Compounds

Coumarin: The Principal Constituent

The tonka seed contains coumarin, a chemical isolate named after the plant. The seeds normally contain about 1 to 3% of coumarin, but can rarely achieve levels up to 10%. Measured concentrations in commercial tonka beans range from 20.4 ± 0.4 to 43.4 ± 0.9 mg coumarin per gram of bean. Chemically, coumarin (1,2-benzopyrone or 2H-1-benzopyran-2-one) and its derivatives, which have a fused structure of a benzene ring and α-pyrone, form a significant family of lactones. Coumarin is a colorless crystalline solid with a sweet odor resembling the scent of vanilla and a bitter taste.

Secondary Phytochemicals

Beyond coumarin, the seeds contain a diverse range of bioactive compounds. Besides coumarin, the seeds contain flavonoids, phenolic acids, and related derivatives with significant antimicrobial and antioxidant activities. A peer-reviewed study published in the Journal of Natural Products identified a complex phytochemical profile: a new cassane diterpene (dipteryxic acid), a new isoflavonolignan (5-methoxyxanthocercin A), as well as known active compounds including isoliquiritigenin, 6,4'-dihydroxy-3'-methoxyaurone, sulfuretin, and (±)-balanophonin, were isolated from an ethyl acetate-soluble extract of the seeds. Other compounds found in Dipteryx odorata seeds include dihydrocoumarin, vanillin, and eugenol. The bark contains isoflavones and umbelliferone, and the leaves are a source of salicylic, hydroxycoumaric, coumaric, and ferulic acids.

Coumarin vs. Coumarin-Derivative Drugs: An Important Distinction

A critical pharmacological distinction applies to tonka bean's principal constituent. While coumarin itself is not an anticoagulant, its 3-alkyl-4-hydroxy derivatives, such as the fungal metabolite dicoumarol, inhibit synthesis of vitamin K, a key component in blood clotting. Coumarin itself does not have significant anticoagulant (blood-thinning) activity. Warfarin is a synthetic derivative with a very different structure and mechanism. While the coumarin derivatives are potent anticoagulants, coumarin itself is completely devoid of anticoagulant activity.

4. Established Mechanisms of Action

Broad Pharmacological Profile of Coumarins

Coumarins and their derivatives exert a vast array of bioactive properties, including anticoagulant, antibacterial, anti-inflammatory, antioxidant, antitumor, antiviral, and enzyme inhibition activities. Higher doses of coumarin are found to be hepatotoxic; however, they exhibit beneficial effects by reducing the risk of cancer and other neuronal and cardiovascular ailments. Most of these effects can be attributed to free radical scavenging.

Anti-Inflammatory Mechanisms

Coumarins reduce edema and inflammation by inhibiting prostaglandin biosynthesis. Hydroxyl aromatic substituted derivatives such as 5-hydroxycoumarin or vicinal dihydroxy coumarins have also been found to be potent anti-inflammatory agents.

Antioxidant Mechanisms

Coumarins such as umbelliferone, esculetin, and quercetin show antioxidant properties and protect cellular DNA from oxidative damage. The antioxidant activity in tonka bean is attributable to both coumarin and the full spectrum of flavonoids and phenolic acids present in the seeds.

Metabolism in Humans

In humans, coumarin is almost completely absorbed from the gastrointestinal tract after oral administration, but is subject to pronounced first-pass metabolism in the liver, so that only about 2 to 6% of the absorbed dose enters the systemic circulation. In humans, unlike in rats, the major metabolic pathway of coumarins is 7-hydroxylation, catalyzed by the CYP2A6 enzyme, which leads to the formation of 7-hydroxycoumarin, excreted in urine as conjugates with glucuronic acid or sulphate. In rats, mice, and dogs, the formation of the hepatotoxic coumarin 3,4-epoxide is predominant — which accounts for the discordance between animal toxicity findings and human outcomes.

Hepatotoxic Mechanism in Susceptible Individuals

In humans with genetic polymorphism of CYP2A6 — specifically the inactivating CYP2A6*2 allele — 7-hydroxylation is deficient, leading to the accumulation of toxic 3,4-coumarin epoxide. Although the genetic polymorphism of this CYP450 isoform is more frequent in Asians, affecting approximately 20% of the population, its precise correlations with known cases of coumarin-induced liver toxicity have not been thoroughly investigated. In vitro studies established that the formation of reactive metabolites is a cytochrome P-450 dependent process and that macromolecular binding can be inhibited by sulphydryl compounds (including reduced glutathione). Coumarin-induced hepatotoxicity in the rat is thus likely mediated via reactive metabolites generated by cytochrome P-450 dependent enzymes.

5. Scientific Evidence by Area of Use

5.1 Lymphedema

The most substantial clinical research on coumarin relates to its pharmaceutical use (as a purified compound, not tonka bean itself) in lymphedema treatment. Coumarin is an effective treatment for primary lymphedema, as well as lymphedema related to breast cancer radiotherapy or surgery. However, its clinical use is limited in several countries due to the possible occurrence of hepatotoxicity, mainly in the form of mild to moderate transaminase elevation.

A clinical trial examining 5,6-benzo-alpha-pyrone (coumarin) in 60 patients with leg lymphedema of varied etiologies found that benzopyrone produced approximately 20% reduction in volume (p = 10⁻⁴) and improvement in circumferences and tonometry (p = 10⁻⁵ and 10⁻⁷). A separate published trial in filarial lymphedema reported that benzopyrone reduced edema for all grades of lymphedema during the year of treatment. Mean monthly reductions in leg volume were 0.62%, 1.1%, and 1.6% for grades 1, 2, and 3–5 respectively.

A Cochrane-registered review of benzo-pyrones for lymphedema included 15 trials. Overall, 15 trials were included that evaluated the role of benzo-pyrones. A meta-analysis of these found that the greater the edema, the greater the rate of reduction, and reductions varied with the molar dose. Side effects were minimal; only oral coumarin may cause idiosyncratic hepatitis at a rate of 3 per 1,000. Topical coumarin does not, nor do other benzo-pyrones.

Contradictory evidence also exists. A randomized controlled trial specifically in women with lymphedema after breast cancer treatment found that volumes of the arms at 6 and 12 months were virtually identical, regardless of whether coumarin or placebo was given first. A review concluded that there remains significant controversy regarding the use and benefits of coumarin, but targeted, appropriate, and monitored use of the drug does appear to have a role in the treatment of lymphedemas. Critically, all of this evidence relates to purified coumarin administered as a pharmaceutical agent, not to tonka bean as a dietary supplement or food ingredient.

5.2 Venous Insufficiency

Among newer vasoprotective agents, the combination of coumarin and troxerutin has shown promise in improving clinical outcomes such as pain reduction, edema control, and quality of life in chronic venous insufficiency. A completed randomized controlled trial (NCT01848210) evaluated a fixed-dose combination of coumarin and troxerutin (Venalot®) versus placebo in chronic venous insufficiency. In addition to dietary exposure, coumarin is used clinically as an antineoplastic agent and for the treatment of lymphedema and venous insufficiency, with clinical administration doses ranging from 11 mg/day for natural food ingredients to up to 7 g/day following clinical administration. These pharmacological uses again involve coumarin as an isolated compound, not tonka bean preparations per se.

5.3 Potential Anticancer Activity

Research has explored the chemopreventive potential of tonka bean seed constituents. The Journal of Natural Products study found that among compounds isolated from D. odorata seeds, isoliquiritigenin exhibited 76% inhibition in a mouse mammary organ culture assay at a dose of 10 μg/mL, based on a bioassay using quinone reductase induction in cultured mouse hepatoma cells. This work is entirely preclinical; no human clinical trials have evaluated tonka bean extracts for cancer outcomes. Higher doses of coumarin are found to exhibit beneficial effects by reducing the risk of cancer. However, this evidence remains at the in vitro and animal level. The coumarin class of phytomolecules has potential to be used as drugs for various diseases, but much work is needed to bring them to the stage of clinical trials for further approval.

5.4 Antimicrobial Activity

A 2026 peer-reviewed study in the International Journal of Molecular Sciences (MDPI) evaluated the antimicrobial activity of D. odorata seed extracts and found that the tonka bean seed ethanol extract (TBSE) possesses strong and broad-spectrum antibacterial activity, with notably low MIC values of 15.6 mg/mL against Gram-negative (E. coli, P. aeruginosa) and Gram-positive (B. licheniformis) bacteria, and 62.5 mg/mL against S. epidermidis. This activity was ascribed to the ethanol extract's ability to capture both coumarin and the associated flavonoids and phenolic acids. This evidence is in vitro only and has not been confirmed in human clinical trials.

5.5 Antioxidant and Anti-inflammatory Activity

Tonka beans and their extracts possess several therapeutic properties including antimicrobial, antioxidant, antifungal, antiviral, antiproliferative, and anti-inflammatory activities. Evidence for these properties is primarily from in vitro and animal studies. Natural coumarins have demonstrated a wide spectrum of pharmacological activities including anti-inflammatory, anticoagulant, anticancer, antibacterial, antimalarial, antifungal, antiviral, Alzheimer's disease inhibition, neuroprotective, and antihypertensive activities — though this body of evidence encompasses the broader class of coumarins, not exclusively those from tonka bean. There are very few studies on the bioavailability of coumarins; therefore, further investigations are needed to study the bioavailability of different coumarins that have shown good biological activities in previous studies.

Overall Evidence Strength Summary

The scientific evidence for tonka bean or its coumarin constituent as a health intervention is, on balance, preliminary and mixed. Purified coumarin has been studied in clinical trials for lymphedema and venous insufficiency with mixed results, but these pharmacological uses employ coumarin as an isolated, dosed pharmaceutical — not tonka bean as consumed. For all other proposed activities (anticancer, antimicrobial, antioxidant, anti-inflammatory), evidence remains at the in vitro or animal level. Although D. odorata has been extensively studied for its timber value and forestry management, comprehensive investigations of its phytochemical composition, toxicity profile, and beneficial properties remain limited.

6. Body Systems and Health Areas of Association

• Lymphatic system: Coumarin from tonka bean has been clinically studied (as isolated compound) for primary and secondary lymphedema.
• Cardiovascular and venous system: Coumarin + troxerutin combinations have been studied for chronic venous insufficiency. The seeds are a historical source of the chemical scaffold from which anticoagulant drugs (warfarin, dicoumarol) were derived.
• Hepatic system: Both a target for potential harm (hepatotoxicity from coumarin at high doses) and a site of first-pass coumarin metabolism via CYP2A6.
• Respiratory system: Traditional use across multiple South American indigenous cultures for coughs, colds, nausea, and respiratory ailments.
• Digestive system: Traditional use for cramps, nausea, and digestive complaints. The seeds are used in the treatment of stomach pain, cough, and dysentery in traditional practice.
• Musculoskeletal system: Topical poultice application for arthritis and muscle pain in traditional Caribbean healing.
• Immune/oncological: Preclinical interest in coumarin and seed constituents as chemopreventive agents; evidence is in vitro only.

7. Dosage Forms and Reported Dosages

No standardized clinical dosage for tonka bean as a whole botanical supplement has been established. No specific official dosage is established, and traditional practices do not stipulate exact amounts.

In clinical pharmacological research on purified coumarin:

• Exposure to coumarin ranges from 11 mg/day for consumption of natural food ingredients to 7 g/day following clinical administration.
• In the lymphedema meta-analysis, reductions varied with the molar dose, approximately 0.10% (SE 0.013%) per dose in mg of coumarin.
• Measured coumarin content in whole commercial tonka beans ranges from 20.4 ± 0.4 to 43.4 ± 0.9 mg per gram of bean.
• In sugars aromatized with tonka, 0.2 ± 0.0 mg/g of coumarin was observed; in two pastes produced from tonka, 0.6 ± 0.0 mg/g was determined.
• The EFSA-derived Tolerable Daily Intake (TDI) for dietary coumarin is 0.1 mg coumarin/kg body weight per day, based on a total safety factor of 100 applied to the NOAEL from a two-year dog study (10 mg/kg bw/day).

8. Safety Considerations and Regulatory Status

Hepatotoxicity

Coumarin is known to be liver toxic, and therefore authorities have regulated its content in foods and alcoholic beverages. Based on available data, coumarin-induced hepatotoxicity is restricted to a small subset of patients, probably due to the activation in these individuals of alternative metabolic pathways involving specific CYP450 isoforms. Only a few cases of severe hepatotoxicity have been described in the literature, with no reported cases of liver failure.

Clinical data on hepatotoxicity from patients treated with coumarin as a medicinal drug revealed a subgroup of the human population being more susceptible to the hepatotoxic effect than the animal species investigated. In 2004, the EFSA concluded that coumarin was not genotoxic in experimental animals, allowing the derivation of a Tolerable Daily Intake. The most sensitive animal species were rats and dogs; based on a two-year dog study, the overall NOAEL for liver toxicity was found to be 10 mg/kg bw per day. EFSA re-evaluated coumarin in 2008 and concluded to maintain the TDI of 0.1 mg coumarin/kg bw allocated in the 2004 opinion.

Genetic Susceptibility

Individuals with certain genetic variations, particularly in the CYP2A6 enzyme, may have a reduced capacity to metabolize coumarin, increasing their susceptibility to its hepatotoxic effects. The use of pharmacogenomics could significantly lower the risk of coumarin-associated hepatotoxicity by targeting the use of coumarin to those with functional CYP2A6.

Animal vs. Human Toxicity: A Species-Specific Consideration

In mid-20th-century animal studies, high doses of coumarin caused significant liver damage in rats and dogs, and researchers flagged it as a possible carcinogen. However, this animal toxicity is partly species-specific: in rats, mice, or dogs, the formation of the hepatotoxic coumarin 3,4-epoxide is predominant, whereas humans primarily metabolize coumarin via the safer 7-hydroxylation pathway. Although adverse effects in humans following coumarin exposure are rare and only associated with clinical doses, recent evidence indicates coumarin causes liver tumors in rats and mice and Clara cell toxicity and lung tumors in mice.

Cosmetic and Skin Safety

Tonka bean absolute contains the natural compound coumarin, which may pose an allergy risk in certain sensitive individuals, and may be photosensitizing.

Regulatory Status by Jurisdiction

Food containing any added coumarin, whether as such or as a constituent of tonka beans or tonka extract, is deemed to be adulterated under the act, based upon an order published in the Federal Register of March 5, 1954. This prohibition is codified under federal regulations, specifically 21 CFR 189.130. Tonka beans may legally be bought, possessed, and used in perfume, cosmetics, and other non-food products in the United States.

Europe manages tonka bean usage through strict coumarin intake limits based on a risk-assessment approach, rather than a total ban. EFSA recommended a maximum level of 0.5 mg/kg in foods. Based on animal data extrapolated to humans, a TDI of 0.1 mg/kg bw coumarin was calculated. In the European Union, the presence of coumarins in food is regulated by Decision No 1334/2008 of the European Parliament and Council, which states that coumarin cannot be added to food as an additive. Alcoholic beverages sold in the European Union are limited to a maximum of 10 mg/l coumarin by law. Belgium also has a ban on tonka beans for food use, enacted in 1977. Tonka beans are generally permitted for use in Canada and Australia, with moderation advised.

Furthermore, coumarin is listed as a naturally occurring substance of possible concern for human health in EFSA's Compendium of Botanicals.

Coumarin Concentration in Products

The European Union has set maximum coumarin levels for various food categories, such as 50 mg/kg in traditional and/or seasonal bakery ware containing a reference to cinnamon in the labeling. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) has evaluated coumarin and established safety guidelines, including an acceptable daily intake similar to EFSA's recommendation. JECFA's assessments inform international food safety standards and regulations.

References

• Wikipedia: Dipteryx odorata
• Toma et al. (2025). Coumarin contents of tonka (Dipteryx odorata) products. European Food Research and Technology.
• Authentication of Tonka beans extracts using LC-UV/MS, GC-MS and multi-element isotope analysis. ScienceDirect.
• An insight into the therapeutic applications of coumarin compounds and their mechanisms of action. PubMed (2020).
• Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms. PMC (2021).
• Coumarin-Induced Hepatotoxicity: A Narrative Review. PMC (2022).
• Review on Natural Coumarin Lead Compounds for Their Pharmacological Activity. PMC (2013).
• A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food and Chemical Toxicology (2006).
• Abraham K. (2010). Toxicology and risk assessment of coumarin: Focus on human data. Molecular Nutrition & Food Research.
• Farinola N & Piller N (2005). Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema. PubMed.
• Chang TS et al. (1996). The use of 5,6-benzo-[alpha]-pyrone and heating by microwaves in the treatment of chronic lymphedema of the legs. PubMed.
• Treatment of filarial lymphoedema and elephantiasis with 5,6-benzo-alpha-pyrone (coumarin). PubMed (1993).
• Benzo-pyrones in the treatment of lymphoedema. PubMed (1999).
• Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. PubMed (1999).
• Investigations into the mechanism of coumarin-induced hepatotoxicity in the rat. PubMed.
• Potential Cancer Chemopreventive Constituents of the Seeds of Dipteryx odorata (Tonka Bean). Journal of Natural Products.
• Evaluation of the Antimicrobial, Cyto-Genotoxic, and Antigenotoxic Activity of Dipteryx odorata Seed Extracts. MDPI IJMS (2026).
• Safety Profile of Nutraceuticals Rich in Coumarins: An Update. Frontiers in Pharmacology (2022).
• eCFR: 21 CFR Part 189 — Substances Prohibited from Use in Human Food (U.S. FDA).
• TGA (Australia): Safety Review — Coumarin for use in topical listed medicines.
• ANSES Opinion: Assessment of the risk of coumarin in food supplements (2019).
• JSTOR Daily: Tonka Bean — The Tale of a Contested Commodity (2025).
• Plants for a Future (PFAF): Dipteryx odorata.
• Useful Tropical Plants: Dipteryx odorata.
• Altmeyers Encyclopedia — Phytotherapy: Coumarin.
• Wikipedia: Coumarin.
• ClinicalTrials.gov: NCT01848210 — Efficacy and Safety of Coumarin and Troxerutin in Chronic Venous Insufficiency.
• Coumarin Derivatives Inhibit ADP-Induced Platelet Activation and Aggregation. PMC (2022).
• Sweet TnT Magazine: Tonka Bean Tree — Traditional Uses in Trinidad & Tobago (2025).
• Salvia Paradise: Tonka Bean Tree Herbarium Entry.